Celebrex for juvenile RA panel review
Pfizer's COX-2 inhibitor Celebrex (celecoxib) for the treatment of juvenile rheumatoid arthritis in patients two years of age and older will be discussed by FDA's Arthritis Advisory Committee Nov. 29. The committee overwhelmingly supported continued marketing of Celebrex during a much publicized 2005 joint meeting with the Drug Safety & Risk Management Advisory Committee on the COX-2 inhibitor class (1"The Pink Sheet" March 7, 2005, p. 21). The November meeting will be held at the Hilton in Gaithersburg, Md. from 8 a.m. to 5 p.m....
You may also be interested in...
FDA Office of Drug Safety Associate Director for Science & Medicine David Graham's controversial presentation of unpublished studies on the safety of COX-2 inhibitors ultimately benefited certain COX-2s and raised questions about others in the class during a joint FDA advisory committee review
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
The HHS was responsible for the most major regulations over the last few years of any agency, an OMB report shows.